8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 20, 2026·SEC
Material company update
Apr 30, 2026·SEC
DNA X, Inc.(SONM)Earnings, Financials & Key Ratios
SONM•NASDAQ
$4.21
Price updated Jul 6, 2026
SectorTechnologyIndustryCommunication EquipmentSub-IndustryPublic Safety and Mission-Critical Radios
AboutSonim Technologies, Inc. provides ruggedized mobile phones and accessories for task workers. The company offers ruggedized mobile phones, such as Sonim XP8, Sonim XP5s, Sonim XP3, and Sonim XP3plus based on the Android platform that are capable of attaching to public and private wireless networks; industrial-grade accessories, including remote speaker microphones, multi-bay charging accessories, and in-vehicle hands-free voice communications solutions; and cloud-based software and application services. It sells its mobile phones and accessories primarily to wireless carriers in the United States and Canada; and sells ruggedized phones, barcode scanners, and accessories through distribution channels in North America, South America, and Europe. The company serves transportation and logistics, construction, manufacturing, facilities management, energy and utility, and public sectors. The company was formerly known as NaviSpin.com, Inc. and changed its name to Sonim Technologies, Inc. in December 2001. Sonim Technologies, Inc. was incorporated in 1999 and is based in Austin, Texas.Show more
- Revenue$0-100.0%
- EBITDA-$1M+96.3%
- Net Income-$21M+38.6%
- EPS (Diluted)-1.59+77.7%
SONM Price & Volume
DNA X, Inc. (SONM) stock price & volume — 10-year historical chart
Loading chart...
Operational Collapse Threatens Long Term Solvency Viability
Investment Thesis • Updated 2026Q1
VerdictNegative: The company's current ratio of 0.76 and the erosion of shareholder equity to -$83
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and solvency
Key Thesis Takeaways
- DNA X, Inc.
- faces a critical existential threat characterized by a total cessation of revenue growth and the complete erosion of shareholder equity, which turned negative at $83,000 in 2026Q1.
- The company's inability to maintain positive operating margins, evidenced by a -147.5% margin in 2024Q4, suggests a fundamental breakdown in its business model.
- Investors should exercise extreme caution as the company's dwindling cash reserves of $1.3 million appear insufficient to support ongoing operations without further dilutive financing.
Verdict Logic
000 indicate an imminent liquidity crisis that makes the stock unsuitable for fundamental investment.
SONM Growth Metrics
DNA X, Inc. (SONM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-128.71%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM51.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-50.04%
Return on Capital
10 Years-126.03%
5 Years-139.14%
3 Years-167.96%
Last Year-
SONM Recent Earnings
DNA X, Inc. (SONM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (27%)●Beat Revenue 1/12 qtrs (10%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$3.11-161.7%
$5.04
Rev
—
$35M
Q1 2026
Jan 30, 2026Metric
Actual
Est
EPS
$10.97-200.0%
$10.97
Rev
$44M-207.1%
$41M
Q4 2025
Oct 31, 2025Metric
Actual
Est
EPS
$3.86-171.5%
$5.40
Rev
$16M-52.8%
$34M
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$10.97-1623.6%
$0.72
Rev
$11M-61.6%
$29M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $3.11vs $5.04-161.7% | —vs $35M |
| Q1 2026 | Jan 30, 2026 | $10.97vs $10.97-200.0% | $44Mvs $41M-207.1% |
| Q4 2025 | Oct 31, 2025 | $3.86vs $5.40-171.5% | $16Mvs $34M-52.8% |
| Q3 2025 | Aug 8, 2025 | $10.97vs $0.72-1623.6% | $11Mvs $29M-61.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for DNA X, Inc. (SONM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.21 | $53.26M | -2.65 | -100% | — | — | — | |
| $0.81 | $8.06M | -0.91 | 13.03% | -55.45% | -79.65% | — | |
| $4.09 | $38.72M | -43.79 | 2.93% | -8.57% | -3.62% | — | |
| $22.09 | $604.02M | -19.38 | 2.91% | -5.77% | -7.97% | — | |
| $2.73 | $11.25M | -0.37 | -15.53% | -165.35% | -141.94% | — | |
| $80.20 | $10.33B | -534.67 | 9.04% | -4.03% | -3.21% | — |
Compare SONM vs Peers
DNA X, Inc. (SONM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SONM SEC Filings & Documents
DNA X, Inc. (SONM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SONM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SONM Frequently Asked Questions
DNA X, Inc. (SONM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is DNA X, Inc.'s revenue?
DNA X, Inc. (SONM) reported $-16.7M in revenue for fiscal year 2025. This represents a 128% decrease from $59.0M in 2017.
How fast is DNA X, Inc. growing?
DNA X, Inc. (SONM) saw revenue decline by 100.0% over the past year.
Is SONM profitable?
DNA X, Inc. (SONM) reported a net loss of $14.8M for fiscal year 2025.
Dividend & Returns
What is DNA X, Inc.'s free cash flow?
DNA X, Inc. (SONM) had negative free cash flow of $17.4M in fiscal year 2025, likely due to heavy capital investments.